234 related articles for article (PubMed ID: 34406363)
1. Cyclin D2 overexpression drives B1a-derived MCL-like lymphoma in mice.
Pieters T; T'Sas S; Vanhee S; Almeida A; Driege Y; Roels J; Van Loocke W; Daneels W; Baens M; Marchand A; Van Trimpont M; Matthijssens F; Morscio J; Lemeire K; Lintermans B; Reunes L; Chaltin P; Offner F; Van Dorpe J; Hochepied T; Berx G; Beyaert R; Staal J; Van Vlierberghe P; Goossens S
J Exp Med; 2021 Oct; 218(10):. PubMed ID: 34406363
[TBL] [Abstract][Full Text] [Related]
2.
Martín-Garcia D; Navarro A; Valdés-Mas R; Clot G; Gutiérrez-Abril J; Prieto M; Ribera-Cortada I; Woroniecka R; Rymkiewicz G; Bens S; de Leval L; Rosenwald A; Ferry JA; Hsi ED; Fu K; Delabie J; Weisenburger D; de Jong D; Climent F; O'Connor SJ; Swerdlow SH; Torrents D; Beltran S; Espinet B; González-Farré B; Veloza L; Costa D; Matutes E; Siebert R; Ott G; Quintanilla-Martinez L; Jaffe ES; López-Otín C; Salaverria I; Puente XS; Campo E; Beà S
Blood; 2019 Feb; 133(9):940-951. PubMed ID: 30538135
[TBL] [Abstract][Full Text] [Related]
3. The pathologic diagnosis of mantle cell lymphoma.
Li S; Xu J; You MJ
Histol Histopathol; 2021 Oct; 36(10):1037-1051. PubMed ID: 34114641
[TBL] [Abstract][Full Text] [Related]
4. Mantle cell lymphoma in cyclin D1 transgenic mice with Bim-deficient B cells.
Katz SG; Labelle JL; Meng H; Valeriano RP; Fisher JK; Sun H; Rodig SJ; Kleinstein SH; Walensky LD
Blood; 2014 Feb; 123(6):884-93. PubMed ID: 24352880
[TBL] [Abstract][Full Text] [Related]
5. A cyclin D1-negative mantle cell lymphoma with an IGL-CCND2 translocation that relapsed with blastoid morphology and aggressive clinical behavior.
Kurita D; Takeuchi K; Kobayashi S; Hojo A; Uchino Y; Sakagami M; Ohtake S; Takahashi H; Miura K; Iriyama N; Sugitani M; Miyoshi H; Hatta Y; Ohshima K; Takei M
Virchows Arch; 2016 Oct; 469(4):471-6. PubMed ID: 27457074
[TBL] [Abstract][Full Text] [Related]
6. Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma.
Chiarle R; Budel LM; Skolnik J; Frizzera G; Chilosi M; Corato A; Pizzolo G; Magidson J; Montagnoli A; Pagano M; Maes B; De Wolf-Peeters C; Inghirami G
Blood; 2000 Jan; 95(2):619-26. PubMed ID: 10627471
[TBL] [Abstract][Full Text] [Related]
7. CCND2 rearrangements are the most frequent genetic events in cyclin D1(-) mantle cell lymphoma.
Salaverria I; Royo C; Carvajal-Cuenca A; Clot G; Navarro A; Valera A; Song JY; Woroniecka R; Rymkiewicz G; Klapper W; Hartmann EM; Sujobert P; Wlodarska I; Ferry JA; Gaulard P; Ott G; Rosenwald A; Lopez-Guillermo A; Quintanilla-Martinez L; Harris NL; Jaffe ES; Siebert R; Campo E; Beà S
Blood; 2013 Feb; 121(8):1394-402. PubMed ID: 23255553
[TBL] [Abstract][Full Text] [Related]
8. Characterization of D-cyclin proteins in hematolymphoid neoplasms: lack of specificity of cyclin-D2 and D3 expression in lymphoma subtypes.
Metcalf RA; Zhao S; Anderson MW; Lu ZS; Galperin I; Marinelli RJ; Cherry AM; Lossos IS; Natkunam Y
Mod Pathol; 2010 Mar; 23(3):420-33. PubMed ID: 20062012
[TBL] [Abstract][Full Text] [Related]
9. Small interfering RNAs targeting cyclin D1 and cyclin D2 enhance the cytotoxicity of chemotherapeutic agents in mantle cell lymphoma cell lines.
Tiemann K; Alluin JV; Honegger A; Chomchan P; Gaur S; Yun Y; Forman SJ; Rossi JJ; Chen RW
Leuk Lymphoma; 2011 Nov; 52(11):2148-54. PubMed ID: 21745168
[TBL] [Abstract][Full Text] [Related]
10. A defect of the INK4-Cdk4 checkpoint and Myc collaborate in blastoid mantle cell lymphoma-like lymphoma formation in mice.
Vincent-Fabert C; Fiancette R; Rouaud P; Baudet C; Truffinet V; Magnone V; Guillaudeau A; Cogné M; Dubus P; Denizot Y
Am J Pathol; 2012 Apr; 180(4):1688-701. PubMed ID: 22326754
[TBL] [Abstract][Full Text] [Related]
11. Development of a murine model for blastoid variant mantle-cell lymphoma.
Ford RJ; Shen L; Lin-Lee YC; Pham LV; Multani A; Zhou HJ; Tamayo AT; Zhang C; Hawthorn L; Cowell JK; Ambrus JL
Blood; 2007 Jun; 109(11):4899-906. PubMed ID: 17311992
[TBL] [Abstract][Full Text] [Related]
12. Differential PAX5 levels promote malignant B-cell infiltration, progression and drug resistance, and predict a poor prognosis in MCL patients independent of CCND1.
Teo AE; Chen Z; Miranda RN; McDonnell T; Medeiros LJ; McCarty N
Leukemia; 2016 Mar; 30(3):580-93. PubMed ID: 26073757
[TBL] [Abstract][Full Text] [Related]
13. SOX11 augments BCR signaling to drive MCL-like tumor development.
Kuo PY; Jatiani SS; Rahman AH; Edwards D; Jiang Z; Ahr K; Perumal D; Leshchenko VV; Brody J; Shaknovich R; Ye BH; Parekh S
Blood; 2018 May; 131(20):2247-2255. PubMed ID: 29615403
[TBL] [Abstract][Full Text] [Related]
14. A cyclin-D1 interaction with BAX underlies its oncogenic role and potential as a therapeutic target in mantle cell lymphoma.
Beltran E; Fresquet V; Martinez-Useros J; Richter-Larrea JA; Sagardoy A; Sesma I; Almada LL; Montes-Moreno S; Siebert R; Gesk S; Calasanz MJ; Malumbres R; Rieger M; Prosper F; Lossos IS; Piris MA; Fernandez-Zapico ME; Martinez-Climent JA
Proc Natl Acad Sci U S A; 2011 Jul; 108(30):12461-6. PubMed ID: 21746927
[TBL] [Abstract][Full Text] [Related]
15. Novel treatment for mantle cell lymphoma including therapy-resistant tumor by NF-κB and mTOR dual-targeting approach.
Chaturvedi NK; Rajule RN; Shukla A; Radhakrishnan P; Todd GL; Natarajan A; Vose JM; Joshi SS
Mol Cancer Ther; 2013 Oct; 12(10):2006-17. PubMed ID: 23963361
[TBL] [Abstract][Full Text] [Related]
16. Cyclin D1-negative mantle cell lymphoma.
Seto M
Blood; 2013 Feb; 121(8):1249-50. PubMed ID: 23429984
[TBL] [Abstract][Full Text] [Related]
17. Characterization of 4 mantle cell lymphoma cell lines.
Amin HM; McDonnell TJ; Medeiros LJ; Rassidakis GZ; Leventaki V; O'Connor SL; Keating MJ; Lai R
Arch Pathol Lab Med; 2003 Apr; 127(4):424-31. PubMed ID: 12683869
[TBL] [Abstract][Full Text] [Related]
18. Early Generated B-1-Derived B Cells Have the Capacity To Progress To Become Mantle Cell Lymphoma-like Neoplasia in Aged Mice.
Hayakawa K; Formica AM; Nakao Y; Ichikawa D; Shinton SA; Brill-Dashoff J; Smith MR; Morse HC; Hardy RR
J Immunol; 2018 Jul; 201(2):804-813. PubMed ID: 29898964
[TBL] [Abstract][Full Text] [Related]
19. CD5-positive, cyclinD1-negative mantle cell lymphoma with a translocation involving the CCND2 gene and the IGL locus.
Shiller SM; Zieske A; Holmes H; Feldman AL; Law ME; Saad R
Cancer Genet; 2011 Mar; 204(3):162-4. PubMed ID: 21504716
[TBL] [Abstract][Full Text] [Related]
20. CDKN1C-mediated growth inhibition by an EZH1/2 dual inhibitor overcomes resistance of mantle cell lymphoma to ibrutinib.
Kagiyama Y; Fujita S; Shima Y; Yamagata K; Katsumoto T; Nakagawa M; Honma D; Adachi N; Araki K; Kato A; Inaki K; Ono Y; Fukuhara S; Kobayashi Y; Tobinai K; Kitabayashi I
Cancer Sci; 2021 Jun; 112(6):2314-2324. PubMed ID: 33792119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
